Artisan Partners Limited Partnership Has $28.44 Million Stock Holdings in Repligen Corporation $RGEN

Artisan Partners Limited Partnership trimmed its stake in shares of Repligen Corporation (NASDAQ:RGEN) by 3.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 212,741 shares of the biotechnology company’s stock after selling 7,786 shares during the quarter. Artisan Partners Limited Partnership owned approximately 0.38% of Repligen worth $28,437,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. Rhenman & Partners Asset Management AB raised its holdings in Repligen by 333.3% during the 2nd quarter. Rhenman & Partners Asset Management AB now owns 19,500 shares of the biotechnology company’s stock worth $2,425,000 after purchasing an additional 15,000 shares during the last quarter. XTX Topco Ltd boosted its stake in shares of Repligen by 34.1% in the 2nd quarter. XTX Topco Ltd now owns 17,352 shares of the biotechnology company’s stock valued at $2,158,000 after purchasing an additional 4,417 shares during the last quarter. Delta Investment Management LLC acquired a new stake in shares of Repligen during the third quarter worth $6,779,000. Congress Asset Management Co. raised its stake in Repligen by 43.4% during the third quarter. Congress Asset Management Co. now owns 218,592 shares of the biotechnology company’s stock worth $29,219,000 after buying an additional 66,142 shares during the last quarter. Finally, Blue Whale Capital LLP acquired a new position in Repligen in the second quarter valued at $35,782,000. 97.64% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on RGEN. Barclays decreased their price target on Repligen from $200.00 to $175.00 and set an “overweight” rating for the company in a report on Wednesday. Weiss Ratings raised Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, February 17th. UBS Group lowered their target price on Repligen from $200.00 to $195.00 and set a “buy” rating for the company in a report on Wednesday. KeyCorp restated an “overweight” rating on shares of Repligen in a report on Wednesday. Finally, Wells Fargo & Company reduced their price objective on shares of Repligen from $190.00 to $180.00 and set an “overweight” rating for the company in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, Repligen currently has a consensus rating of “Moderate Buy” and a consensus target price of $174.58.

Repligen Stock Down 3.7%

Shares of NASDAQ:RGEN opened at $128.73 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.14 and a current ratio of 8.37. Repligen Corporation has a 52-week low of $102.96 and a 52-week high of $175.77. The business’s 50 day simple moving average is $154.18 and its two-hundred day simple moving average is $146.97. The firm has a market cap of $7.25 billion, a P/E ratio of 151.45, a PEG ratio of 2.44 and a beta of 1.13.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. Repligen had a return on equity of 4.71% and a net margin of 6.62%.The company had revenue of $197.91 million for the quarter, compared to analyst estimates of $192.23 million. During the same period in the prior year, the firm earned $0.44 earnings per share. Repligen’s revenue for the quarter was up 18.1% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. As a group, research analysts forecast that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Insiders Place Their Bets

In other Repligen news, Director Karen A. Dawes sold 275 shares of the firm’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $161.00, for a total value of $44,275.00. Following the transaction, the director directly owned 91,821 shares of the company’s stock, valued at approximately $14,783,181. This trade represents a 0.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.20% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.